Leaving BNY Website

 

You are leaving the BNY Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2024 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
 

To learn more about DRs, please contact DRBrokerSolutions@bnymellon.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures FTSE +0.18%, DAX30 +0.56%, CAC40 +0.01%

Nov 20 ,2024

  • Synopsis

    • European equity markets are set to open in positive territory amidst mixed Asian equities on Wednesday. Greater China markets little changed while Japan and Australia seeing mild declines. S&P 500 futures higher afterhours.

    • Debate is heating up within Germany's SPD as to whether Scholz is still the right candidate for chancellor. SPD senior figures held a telephone conf on Tuesday, but no results have been made public. Pressure is piling on Scholz to let someone else lead his Social Democrats into the Feb-25 snap election. There are growing calls in the SPD for Scholz to step aside in favour of his more popular defence minister, Boris Pistorius (Welt , Reuters , Süddeutsche Zeitung).

    • In the UK, weekly PMQs at 12noon GMT, whilst Sec. of State at Scotland Office before committee at 9:30, with other committee topics include Work of the Dept for Energy Security and Net Zero at 15:00 (speakers include Chair at Great British Energy). Norway's defence minister Gram attends meetings in the Northern Group - UK-led format involves 12 countries - 3 Baltic countries, 5 Nordic countries, Poland, the Netherlands and Germany, and the Nordic-Baltic Eight (NB8), both in Copenhagen. Also, OMFIF / Frankfurt School of Finance and Management event on macroeconomics and capital markets.

    • On the central bank front, ECB publishes at 10:00CET its latest Financial Stability Review and ECB's Lagarde speech at 14:00CET at ECB conf on financial stability and macroprudential policy 2024, with ECB's de Guindos speech ay 19:00CET. BOE's Ramsden speech at 16:00GMT on monetary policy at the Univ. of Leeds whilst Bank of Greece's Stournaras speech at 18:30GMT at event organised by Birkbeck, Univ of London. Ireland central bank's Makhlouf speech at 19:00GMT at Financial Services Ireland Annual Dinner and Latvia central bank's Kazāks participates in a discussion on LTV. BaFin annual conference of insurance supervision.

    • Macro data due include UK Oct CPI/RPI/PPI input/output, Germany Oct PPI, Denmark Q3 preliminary GDP and Eurozone Sep construction output.

    • In earnings, SGS (SGSN.SW) is hosting its CMD where it said it focuses on Strategy 27 and confirms financial objectives and willa acquire MP Machinery. dormakaba Holding (DOKA.SW) also reiterated its mid-term targets ahead of its CMD. In France, STMicroelectronics (STMPA.FP) reiterated its $20B+ revenue ambition by 2030 in connection with its CMD and introduces 2027-2028 intermediate model whilst VINCI (DG.FP) reported Oct airport passenger traffic, +6.2%. Renalytix (RENX.LN) reported Q1 GAAP EPS ($0.04) vs year-ago ($0.11).

    • On the M&A front, Symrise (SY1.GR) made an offer to acquire Probi for SEK350/share in cash whilst Bloomberg reported Rubis (RUI.FP) is exploring a potential sale. Grifols (GRF.SM) said its board would not recommend shareholders accept potential offer by Brookfield (BAM) at indicated price.

    • CMD/investor events hosted by STMicroelectronics (STMPA.FP), Nexans (NEX.FP), SGS (SGSN.SW), dormakaba Holding (DOKA.SW), F-Secure (FSECURE.FH), Sinch (SINCH.SS) and Deutsche Rohstoff (DR0.GR).

  • Macro

    • G-20 Ends in a Whimper After Lula Skips Closing Remarks - Bloomberg

    • Putin, ascendant in Ukraine, eyes contours of a Trump peace deal - Reuters

    • Pressure grows on Germany's Scholz over bid for second term - Reuters

  • Top company news

    • Earnings/updates

      • DACHs:

        • SGSN.SW (SGS) -- focuses on Strategy 27 at its Capital Markets Event, fully confirms financial objectives, acquires MP Machinery

        • DOKA.SW (dormakaba Holding) -- reiterates its mid-term targets - CMD

        • EFGN.SW (EFG International) -- reports 10-months business update: net new assets CHF 7.4B, corresponding to annualised growth rate of 6.3%

        • BALN.SW (Baloise) -- reports YTD business volume CHF6.89B as of 30-Sept vs year-ago CHF6.94B

        • KTCG.AV (Kapsch TrafficCom) -- reports H1 EPS (€0.73) including items vs year-ago €3.59; reaffirms FY2024/25 outlook

      • France:

        • STMPA.FP (STMicroelectronics) -- reiterates $20B+ revenue ambition by 2030; introduces 2027-2028 intermediate model -- CMD

        • DG.FP (VINCI SA) -- Vinci Airports Oct airport passenger traffic, +6.2%

      • Nordics:

        • EOLU.B.SS (Eolus Vind) -- reports Q3 EPS (SEK3.16) vs FactSet (SEK1.30) [1 est]

        • PEN.NO (Panoro Energy) -- reports Q3 EPS $0.00 vs year-ago $0.24

        • NRC.NO (NRC Group) -- reports Q3 EPS (NOK0.13) vs year-ago NOK0.66

      • UK:

        • RENX.LN (Renalytix) -- reports Q1 GAAP EPS ($0.04) vs year-ago ($0.11) - 10-Q

      • Southern Europe:

        • TLGO.SM (Talgo) -- reports 9M net income €6.7M vs FactSet €8.4M

    • M&A

      • GIMB.BB (Gimv) -- sells it's majority stake in outpatient rehabilitation specialist rehaneo to Fremman Capital

      • GRF.SM (Grifols) -- announces board would not recommend shareholders accept potential offer by Brookfield at indicated price

      • RUI.FP (Rubis) -- exploring potential sale - Bloomberg

      • PROB.SS (Probi) --

        • Symrise offers to acquire Probi for SEK350/share in cash

        • Probi's independent bid committee will now evaluate the Symrise's public takeover offer

      • SRI.IM (Servizi Italia) -- Cometa S.r.l. (owned by Aurum and Coopservice) announces final result of offer for Servizi Italia; holds ~95.1% (post EU close 19-Nov)

      • SGSN.SW (SGS) -- focuses on Strategy 27 at its Capital Markets Event, fully confirms financial objectives, acquires MP Machinery

      • SDG.FP (Synergie) -- announces acquisition of minority shareholder's stake in Italia

      • ALHEX.FP (Hexaom) -- Follow-up: Hexaom reports Q3 revenue €144.7M, (29%) vs year-ago €203.6M

    • Healthcare

      • NOVO.B.DC (Novo Nordisk) -- announced results from part 1 of the ongoing Phase 3 ESSENCE trial. Part 1 evaluated the effect of once-weekly subcutaneous semaglutide 2.4 mg on liver tissue (histology)

      • UCB.BB (UCB) -- receives US FDA approval for BIMZELX (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa

      • INDV.LN (Indivior) -- presents data demonstrating rapid initiation (RI) with once-monthly SUBLOCADE superior to standard initiation for treating opioid use disorder at CSAM 2024

      • ABVX.FP (Abivax) --

        • files $350M equity shelf - F-3

        • enters into ATM program of up to $150M ADS' with Piper Sandler

      • RENX.LN (Renalytix) -- SEC filing: 10-Q

      • ORNBV.FH (Orion) -- and Alligator Bioscience amend their agreement concerning two bispecific antibodies

      • IBAB.BB (Ion Beam Applications) -- signs contract with Benebion for the installation of a Rhodotron at a facility in Mexico

      • ATORX.SS (Alligator Bioscience) -- Follow-up: Alligator announces sale of future financial commitments for two bispecific antibodies to Orion Corporation

    • Other

      • EBUS.NA (Ebusco Holding) -- completes €36M rights issue

      • NOKIA.FH (Nokia) -- T-Mobile (TMUS) says it hasn't made any decision to end supplier relationship with Nokia -- Bloomberg

      • ML.FP (Cie Generale des Etablissements Michelin SA) -- Michelin publishes global tire market data for Oct

      • EDEN.FP (Edenred) -- increases share buyback mandate by €39M

      • BORR.NO (Borr Drilling) -- receives notice of temporary suspension of operation for its rig "Arabia II", operating in Saudi Arabia

      • HTWS.LN (Helios Towers) -- Holder Arbejdsmarkedets Tillægspension to place ~50.6M shares in Helios Towers plc via BofA Securities

      • Boeing, Raytheon and BAE Systems named primary contractors for $6.2B sale to Republic of Korea

      • State Department approves possible Foreign Military Sale to Korea of F-15K Aircraft Upgrade

  • Key rating changes

    • Upgrades

      • COL.SM (Inmobiliaria Colonial SOCIMI) -- buy from neutral at JB Capital Markets

      • EQNR.NO (Equinor) -- to buy from neutral at Redburn Atlantic

      • REMEDY.FH (Remedy Entertainment) -- to buy from accumulate at Inderes

      • Bernstein upgrades EDP.PL, EDPR.PL

      • JPMorgan upgrades BZU.IM, HOLN.SW

      • AZN.LN (AstraZeneca) -- to neutral from sell at UBS

      • EDEN.FP (Edenred) -- to hold from underperform at Jefferies

      • UU.LN (United Utilities Group) -- to buy from hold at Deutsche Numis

    • Downgrades

      • GLPG.NA (Galapagos) -- to reduce from hold at Kepler Cheuvreux

      • EZJ.LN (EasyJet) -- to hold from buy at HSBC (timing uncertain)

      • SSPG.LN (SSP Group) -- to neutral from overweight at JPMorgan

      • PHLL.LN (Petershill Partners) -- to hold from buy at Deutsche Numis

    • Other Actions

      • Barclays transfers ABN.NA, INGA.NA, KBC.BB

      • NCAB.SS (NCAB Group) -- initiated buy at Pareto

      • LNA.FP LNA (Santé) -- initiated buy at Kepler Cheuvreux

      • YUBICO.SS (Yubico) -- initiated buy at Nordea

      • AVOL.SW (Avolta) -- initiated buy at Berenberg

      • SGRO.LN (Segro) -- resumed hold at Jefferies; prior rating was hold

      • NEL.NO (NEL) -- reinitiated reduce at Kepler Cheuvreux

  • Data

    • Nikkei (0.16%) to 38352.34

    • Hang Seng +0.13% to 19688.83

    • Shanghai Composite +0.44% to 3360.64

    • S&P futures +14.8 vs prior close of 5938.8

    • €-$ (0.0007) or (0.07%) to 1.0589

    • $-¥ +0.72 or +0.47% to 155.38

    • €-¥ +0.62 or +0.38% to 164.50

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE